Skip to main content

letter

. 1994 Apr;69(4):792. doi: 10.1038/bjc.1994.150

Verapamil: what is the mechanism of its anticarcinogenic activity?

PMCID: PMC1968799 PMID: 8142268

792

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Burt R. K., Thorgeirsson S. S. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst. 1988 Nov 2;80(17):1383–1386. doi: 10.1093/jnci/80.17.1383. [DOI] [PubMed] [Google Scholar]
Ford J. M., Hait W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990 Sep;42(3):155–199. [PubMed] [Google Scholar]
Tsuda H., Lee G., Farber E. Induction of resistant hepatocytes as a new principle for a possible short-term in vivo test for carcinogens. Cancer Res. 1980 Apr;40(4):1157–1164. [PubMed] [Google Scholar]
Uehara H., Nakaizumi A., Baba M., Iishi H., Tatsuta M. Inhibition by verapamil of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer. 1993 Jul;68(1):37–40. doi: 10.1038/bjc.1993.283. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES